{"doi":"10.1111/1759-7714.13241","title":"Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody","abstract":"<jats:sec><jats:title>Background</jats:title><jats:p>This study evaluated the efficacy and safety of retreatment with anti‐programmed death 1 (anti‐PD‐1) antibodies in patients with advanced non‐small cell lung cancer (NSCLC) after prior treatment with anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibodies.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Data (<jats:italic>N</jats:italic> = 15) on patients' characteristics, number of cycles, regimens, their best response and immune‐related adverse events (irAEs) were recorded retrospectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>NSCLC was initially treated with anti‐PD‐L1 antibody atezolizumab (<jats:italic>N</jats:italic> = 14) or durvalumab (<jats:italic>N</jats:italic> = 1). No patients had a high (≥50%) tumor expression of PD‐L1. The median cycles for atezolizumab were five (range 1–15), and median progression‐free survival was 2.8 and 6.0 months for atezolizumab and durvalumab, respectively. Five (33.3%) and nine (60.0%) patients showed stable and progressive disease as their best response, respectively. No differences in irAEs between anti‐PD‐L1 and anti‐PD‐1 antibodies occurred.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Patients treated with anti‐PD‐L1 antibodies for NSCLC received limited benefits from retreatment with anti‐PD‐1 antibodies.</jats:p></jats:sec>","journal":"Thoracic Cancer","year":2020,"id":644310,"datarank":2.951001260159387,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"self_citation_contribution":0.5775221402565088,"citation_network_contribution":2.3734791199028784,"self_endowment_contribution":0.5775221402565088,"citer_contribution":2.3734791199028784,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":44,"citers_with_citation_signal":39,"citers_with_endowment":39,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":617539,"name":"Yuki Yamamoto","orcid":"0000-0001-9317-7267","position":1,"is_corresponding":false},{"id":1547239,"name":"Osamu Kanai","orcid":"0000-0003-0736-3317","position":2,"is_corresponding":false},{"id":1547240,"name":"Misato Okamura","orcid":null,"position":3,"is_corresponding":false},{"id":1568674,"name":"Masayuki Hashimoto","orcid":null,"position":4,"is_corresponding":false},{"id":1547241,"name":"Koichi Nakatani","orcid":null,"position":5,"is_corresponding":false},{"id":1676927,"name":"Satoru Sawai","orcid":null,"position":6,"is_corresponding":false},{"id":1547242,"name":"Tadashi Mio","orcid":null,"position":7,"is_corresponding":false},{"id":1547237,"name":"Kohei Fujita","orcid":"0000-0002-6902-9085","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody","abstract":"<jats:sec><jats:title>Background</jats:title><jats:p>This study evaluated the efficacy and safety of retreatment with anti‐programmed death 1 (anti‐PD‐1) antibodies in patients with advanced non‐small cell lung cancer (NSCLC) after prior treatment with anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibodies.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Data (<jats:italic>N</jats:italic> = 15) on patients' characteristics, number of cycles, regimens, their best response and immune‐related adverse events (irAEs) were recorded retrospectively.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>NSCLC was initially treated with anti‐PD‐L1 antibody atezolizumab (<jats:italic>N</jats:italic> = 14) or durvalumab (<jats:italic>N</jats:italic> = 1). No patients had a high (≥50%) tumor expression of PD‐L1. The median cycles for atezolizumab were five (range 1–15), and median progression‐free survival was 2.8 and 6.0 months for atezolizumab and durvalumab, respectively. Five (33.3%) and nine (60.0%) patients showed stable and progressive disease as their best response, respectively. No differences in irAEs between anti‐PD‐L1 and anti‐PD‐1 antibodies occurred.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Patients treated with anti‐PD‐L1 antibodies for NSCLC received limited benefits from retreatment with anti‐PD‐1 antibodies.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31701630","pmcid":"PMC6938769","openalex_id":"https://openalex.org/W2982865941","authors":[],"funders":[],"total_grants":0,"fwci":1.6997,"citation_percentile":0.86504486,"influential_citations":0,"citation_trend":[{"year":2020,"count":5},{"year":2021,"count":6},{"year":2022,"count":8},{"year":2023,"count":6},{"year":2024,"count":12},{"year":2025,"count":6},{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1759-7714.13241","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1759-7714.13241","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2F1759-7714.13241","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13241","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1759-7714.13241","host_type":"publisher"},{"url":"https://doi.org/10.1111/1759-7714.13241","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31701630","host_type":"repository"},{"url":"https://doaj.org/article/20f6eacaab7b432d98ad266e2d1a8020","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6938769","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC6938769","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC6938769?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Lung Cancer Research Studies","Immunotherapy and Immune Responses"],"mesh_terms":["Antineoplastic Agents, Immunological","Aged","Carcinoma, Non-Small-Cell Lung","Female","Follow-Up Studies","Humans","Lung Neoplasms","Male","Prognosis","Retrospective Studies","Biomarkers, Tumor","Survival Rate","Salvage Therapy","Retreatment","B7-H1 Antigen","Programmed Cell Death 1 Receptor"],"keywords":["Atezolizumab","Durvalumab","Medicine","Antibody","Internal medicine","Adverse effect","Lung cancer","PD-L1","Oncology","Immunotherapy","Nivolumab","Cancer","Gastroenterology","Immunology","Retreatment","Anti-pd-1","Immune Checkpoint Inhibitors","Anti-pd-l1"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T00:52:40.882055Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}